Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation

Oxidative Medicine and Cellular Longevity

Volumn 2, Issue 2, 2009, Pages 82-87

  Gonçalves, Thissiane L ^a   Benvegnù, Dalila M ^a   Bonfanti, Gabriela ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Bone marrow transplantation; Conditioning regimen; Engraftment; Hematopoietic stem cell transplantation; Peripheral blood stem cell transplantation

Indexed keywords

ARABINOSIDE; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; OVERALL SURVIVAL; THROMBOCYTE COUNT; ADOLESCENT; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77953371391     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.4161/oxim.2.2.8355     Document Type: Article

References (27)

1. Milla C, Yang S, Cornfiel DN, Brennan ML, Hazen SL, Mortari AP, et al. Myeloperoxidase deficiency enhances inflammation after allogenic marrow transplantation. Am J Physiol Lung Cell Mol Physiol 2004; 287:706-14.
2. Armitage JO. Medical progress: bone marrow transplantation. N Engl J Med 1994; 330:827-38.
3. Horning SJ, Nademanee AP. Autologous hematopoietic cell transplantation for non- Hodgking lymphoma. Blackwell Science 1999; 939-51.
4. Oyan B, Koc Y, Ozdemir E. Ifosfamide, idarubicin and etoposide in relapsed/refractory Hodgkin disease or non-Hodgking lymphoma: a savage regimen with high response rates before autologous stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:688-97.
5. Clift RA, Anasetti C. Allografting for chronic myeloid leukaemia. Baillieres Clin Haematol 1997; 10:319-36.
6. Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14:165-70.
7. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13:1328-35.
8. Hartmann O, Le Corroler AG, Blaise D, Michon J, Philip I, Norol F, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs-a randomizad, controlled trial. Ann Intern Med 1997; 126:600-7.
9. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transportation. Blood 2000; 95:3702-9.
10. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85:1655-8.
11. Tayebi H, Lapierre V, Saas P, Lienard A, Sutton L, Milpied N, et al. Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft. Br J Haematol 2001; 114:698-700.
12. Robinet E, Lapierre V, Tayebi H, Kuentz M, Blaise D, Tiberghien P. Blood versus marrow hematopoietic allogeneic graft. Transfusion and Apheresis Science 2003; 29:53-9.
13. Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A, et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol Blood Marrow Transplant 2008; 14:301-8.
14. Devetten M, Armitage JO. Hematopoietic cell transplantation: progress and obstacles. Ann Oncol 2007; 18:1450-6.
15. Ziegler TM. Glutamine supplementation in bone marrow transplantation. Br J Nutrition 2002; 87:9-15.
16. Rizzo JD. Current trends in BMT. ABMTR News Letter 1998; 5:4-10.
17. Bacigalupo A, Zikos P, Van Lint MT, Valbonesi M, Lamaprelli T, Gualandi F, et al. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience. Exp Hematol 1998; 26:409-14.
18. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced henatologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88:2794-800.
19. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97:3380-9.
20. Carral A, de la Rubia J, Martãn G, Martãnez J, Sanz G, Jarque I, et al. Factors influencing hematopoietic recovery after blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Bone Marrow Transplant 2002; 29:825-32.
21. th Ed. São Paulo, SP:BBS 2006; 85-7.
22. Srinivasan R, Takahashi Y, Mccoy JP, Espinoza-Delgado I, Dorrance C, Igarashi T, et al. Overcoming graft rejection in heavily trasnfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol 2006; 133:305-14.
23. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloblative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood 1998; 91:756-63.
24. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al. Regression of metastic renal-cell carcinoma after nonmyeloblative allogenic peripheral-blood stemcell transplantation. New England Journal of Medicine 2000; 343:750-8.
25. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mis-matched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolato mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101:1620-9.
26. Kang HJ, Shin HY, Choi HS, Ahn HS. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant 2004; 34:939-43.
27. George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M. Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia. Pediatr transplant 2008; 12:14-9.